Risk factors
Candel Therapeutics (CADL) risk factors
Item 1A of every Candel Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors104 risks10 new12 dropped22 reworded
Candel Therapeutics added financial and intellectual property covenants tied to the new RTW Purchase Agreement. The company updated drug candidate names from CAN-2409 and CAN-3110 to aglatimagene and linoserpaturev. New risks address banking sector instability, privacy laws, and patent enforcement changes.
Filed Mar 12, 2026 - FY2024 10-K risk factors106 risks
Candel Therapeutics faces extensive financial losses with no commercial revenue, relying heavily on the success of its lead viral immunotherapies CAN-2409 and CAN-3110.
Filed Mar 13, 2025